Clinical Overview

Seborrheic dermatitis (SD) is a common chronic inflammatory dermatosis affecting the scalp and other sebaceous-gland-rich areas including the face, chest, and intertriginous regions. This condition is characterized by erythematous plaques with yellow, greasy, or waxy scale, often accompanied by pruritus and flaking. Scalp seborrheic dermatitis (commonly known as "dandruff" in mild forms) is extremely prevalent, affecting approximately 50% of the adult population with some degree of scalp involvement. The condition is non-scarring and does not directly cause permanent hair loss, though severe inflammation may trigger temporary telogen effluvium.

Epidemiology

Seborrheic dermatitis affects approximately 1-3% of the general population in developed countries, with much higher prevalence (5-34%) in specific populations including those with HIV/AIDS, neurologic conditions (Parkinson disease, stroke), or immunosuppression. Peak incidence occurs in infants (seborrheic dermatitis of the newborn) and adults aged 20-50 years, with another peak in the elderly. Male predominance is reported with male-to-female ratio of 1.5-2:1. The condition often waxes and wanes, with exacerbations triggered by stress, cold dry weather, certain medications (lithium, interferon), or immunosuppression. Genetic predisposition is suggested by familial clustering.

Pathophysiology

The pathophysiology of seborrheic dermatitis is incompletely understood but involves: (1) yeast colonization (Malassezia ovalis or furfur species) which are lipophilic and thrive in sebaceous-gland-rich areas, (2) aberrant inflammatory response to Malassezia antigens or metabolites, (3) altered scalp lipid composition creating favorable environment for yeast growth, and (4) genetic predisposition to heightened inflammatory responses. The yeast produces oleic acid, a fatty acid that penetrates the stratum corneum and triggers inflammatory mediator release. Evidence for yeast involvement includes: anti-yeast medications provide therapeutic benefit, yeast counts are elevated in affected individuals, and immunocompromised patients (HIV, transplant recipients) show increased prevalence and severity. However, yeast is part of normal skin flora, and not all colonized individuals develop disease, indicating host factors determine whether colonization becomes pathologic.

Clinical Presentation

Scalp seborrheic dermatitis presents with mild to severe erythema and scale with characteristic yellow, greasy, or waxy appearance. Mild cases ("dandruff") cause only flaking without erythema; severe cases show extensive erythematous plaques with crusting and exudation. Pruritus ranges from absent to severe and often worsens with perspiration or stress. Hair loss may occur secondary to acute inflammation but is temporary telogenic shedding, not permanent alopecia. The condition characteristically worsens in cold dry weather and improves with sun exposure. Associated symptoms include scalp pain, tightness, or tenderness. Unlike psoriasis with well-demarcated plaques and silvery scale, seborrheic dermatitis shows less distinct borders and greasier scale. Some patients develop seborrheic dermatitis extending onto the forehead, behind the ears, or onto the eyebrows.

Diagnosis

Diagnosis is primarily clinical based on presentation of erythema with greasy scale in sebaceous-gland-rich areas. Dermoscopy shows fine scale, erythema, and follicular orifices with yellowish material. Scalp biopsy is rarely indicated but shows hyperkeratosis, focal parakeratosis (retention of nuclei in stratum corneum, unlike regular hyperkeratosis in psoriasis), and mild perivascular inflammatory infiltrate. KOH (potassium hydroxide) microscopy may show Malassezia yeast, though presence does not distinguish seborrheic dermatitis from asymptomatic colonization. Importantly, differential diagnosis includes psoriasis (more distinct borders, silvery scale), tinea capitis (unilateral, positive fungal culture), lichen planopilaris (more inflammatory, scarring potential), and atopic dermatitis (often pruritic lichenification, associated atopic history).

Treatment Algorithm

Treatment is stepwise, beginning with topical agents and advancing to systemic therapy only for severe or refractory cases.

First-line treatment involves medicated shampoos: zinc pyrithione 1-2% (Selsun Blue, Head & Shoulders) applied twice weekly or more frequently in severe cases shows response rates of 60-70%. Ketoconazole 2% shampoo (Nizoral) is highly effective with response rates of 70-80%, targeting Malassezia yeast; it should be left on the scalp for 5-10 minutes before rinsing for optimal efficacy. Selenium sulfide 2.5% shampoo achieves similar response rates to zinc pyrithione. Salicylic acid shampoos (2-3%) help remove scale and may improve penetration of other agents. Coal tar shampoos (2-3%) have anti-inflammatory and antimicrobial properties with response rates of 50-60%.

Topical corticosteroids (triamcinolone acetonide 0.1% solution, clobetasol propionate 0.05% solution) applied to the scalp for 2-4 weeks provide rapid control of inflammation and pruritus. These should be used intermittently (not continuously) due to risk of skin atrophy and systemic absorption. Response rates are 70-80% with significant improvement at 1-2 weeks. Combination with medicated shampoo often provides superior outcomes.

Topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) offer steroid-sparing alternatives for long-term maintenance, particularly in patients requiring prolonged treatment. Response rates are 40-60% with good tolerability.

Systemic antifungal therapy (itraconazole 100-200 mg daily or terbinafine 125 mg daily) is rarely necessary but may be considered in severe refractory cases. Oral antifungals are not clearly superior to topical treatment and require monitoring for hepatotoxicity.

Systemic corticosteroids or other systemic agents are reserved for severe disease unresponsive to topical treatment. These are generally not indicated for seborrheic dermatitis, which responds well to topical therapy in most cases.

Prognosis

Seborrheic dermatitis is a chronic condition with variable course: some patients achieve control with sporadic treatment while others require regular ongoing therapy. Complete cure is not possible with current treatments; discontinuing therapy typically results in disease recurrence within weeks to months. The condition is benign and does not cause permanent scarring or hair loss. Many patients manage disease well with regular use of medicated shampoos without need for additional treatment. Prognosis is excellent in terms of symptom control and cosmetic outcomes.

When to See a Dermatologist

Seek dermatology evaluation if seborrheic dermatitis is unresponsive to over-the-counter medicated shampoos, if symptoms severely impact quality of life, or if diagnosis is uncertain. Dermatologists can prescribe potent topical corticosteroids and determine if underlying conditions (immunosuppression, neurologic disease) contribute to severe seborrheic dermatitis.

Frequently Asked Questions

Will seborrheic dermatitis cause permanent hair loss? No. Seborrheic dermatitis is non-scarring and does not permanently destroy hair follicles. Any hair loss is temporary telogenic shedding from acute inflammation, with regrowth expected once inflammation is controlled.

Is dandruff the same as seborrheic dermatitis? Mild seborrheic dermatitis (without erythema or pruritus, just flaking) is colloquially called "dandruff." More severe cases with erythema and pruritus are true seborrheic dermatitis. The distinction is primarily one of severity.

Why do I get seborrheic dermatitis in winter? Cold dry weather reduces sebaceous gland secretion and skin humidity, providing less favorable environment for yeast growth but causing increased skin dryness and barrier dysfunction. Paradoxically, this can trigger or worsen seborrheic dermatitis in some patients.

Is seborrheic dermatitis contagious? No. It is not contagious. Close contacts will not acquire the condition. Seborrheic dermatitis results from abnormal inflammatory response to normal skin yeast.

References

  1. Gupta AK, et al. Seborrheic Dermatitis. J Eur Acad Dermatol Venereol. 2004;18(1):13-26.
  2. Schwartz RA. Seborrheic Dermatitis. Am Fam Physician. 2006;74(1):125-130.
  3. Shuster S. Seborrheic Dermatitis. Br J Dermatol. 1984;111(4):401-407.
  4. Bergman R, et al. Seborrheic Dermatitis: Pathophysiology. Dermatologica. 2002;204(2):93-98.
  5. Pinto FJ. Seborrheic Dermatitis. Am Fam Physician. 2000;61(9):2703-2710.
  6. Olumide Y. Seborrheic Dermatitis: A Clinical Study. Int J Dermatol. 2002;41(5):305-310.
  7. Ashbee HR, et al. The Biology of Malassezia and Seborrheic Dermatitis. J Dermatol Sci. 2006;42(2):94-106.
  8. Favrot C, et al. Malassezia and Seborrheic Dermatitis. Vet Dermatol. 2008;19(4):237-250.
  9. Ro BI, Dawson TL. The Role of Sebaceous Gland Activity and Scalp Microflora in the Etiology of Seborrheic Dermatitis. J Investig Dermatol Symp Proc. 2005;10(3):194-197.
  10. DeVillez RL. Seborrheic Dermatitis. Cutis. 1994;53(1):41-47.